Zoetis is trading 4.04% down at $78.79 on November 6, following its Q3 2026 earnings report released yesterday. - Third-quarter revenue fell 1% year over year to $2.4 billion, and net income dropped 18% to $591 million. - Adjusted EPS of $1.75 beat estimates, and Zoetis raised its full-year adjusted EPS outlook. - U.S. companion-animal revenue decreased 8%, reflecting macro-driven price sensitivity and competitive pressure in dermatology and generics.